$4.12
-0.09-2.14%
Last update: Nov 13, 1:01 PM
Taysha Gene Therapies Inc
TSHANASDAQ
Taysha Gene Therapies rose 5.0% from $4.01 to $4.21, behind the S&P 500's +12.7%. Its worst day was Jul 13 (−15.1%), and its low came Oct 14 at $3.51.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Taysha Gene Therapies shares rose 12.7%, while the S&P 500 rose 0.1%.
+12.7% · S&P 500 +0.1%
EPS of $-0.12 missed the $-0.10 estimate on $5.5M revenue (est. $1.9M).
+2.5% · S&P 500 −0.5%
Story events cover the past 12 months · Times ET
Taysha Gene Therapies shares rose 27.4%, while the S&P 500 rose 0.8%.
+27.4%, the year's best day · S&P 500 +0.8%
EPS of $-0.12 missed the $-0.10 estimate on $0.00 revenue (est. $758,330.00).
+0.6% · S&P 500 +1.4%
Taysha Gene Therapies shares fell 15.1%, while the S&P 500 fell 0.8%.
−15.1%, the year's worst day · S&P 500 −0.8%
EPS of $-0.13 missed the $-0.11 estimate on $0.00 revenue (est. $618,180.00).
−4.1% · S&P 500 +0.3%
Taysha Gene Therapies closed at its lowest level of the year, 12.5% below where the year started.
−2.0% · S&P 500 −1.1%
EPS of $-0.10 beat the $-0.13 estimate on $0.00 revenue (est. $618,180.00).
−1.6% · S&P 500 −0.4%
Where it ended: a close of $4.21 on Nov 12, 2026.
Nothing in the past 12 months.
All TSHA dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TSHA and SPY from Benzinga historical bars. Not investment advice.
